Comparison of effectiveness of Liposomal Cisplatin combined with Paclitaxel versus Cisplatin combined with Paclitaxel in patients with adenocarcinoma and undifferentiated carcinoma of the lungs.

Trial Profile

Comparison of effectiveness of Liposomal Cisplatin combined with Paclitaxel versus Cisplatin combined with Paclitaxel in patients with adenocarcinoma and undifferentiated carcinoma of the lungs.

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jul 2016

At a glance

  • Drugs Cisplatin (Primary) ; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 08 Jul 2011 Additional primary endpoints added as reported by Australian New Zealand Clinical Trials Registry.
    • 08 Jul 2011 New source added and integrated (ACTRN12610000046000, Australian New Zealand Clinical Trials Registry).
    • 08 Jul 2011 Actual initiation date (Sep 2007) added as reported by Australian New Zealand Clinical Trials Registry.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top